Characteristics of the patients and univariate associations with overall survival
| . | n (%) . | Hazard ratio for event (95% CI) . | P . |
|---|---|---|---|
| Sample | |||
| Sample size, cases | 1003 | ||
| Follow up, median (range), y | 5.8 (0-18) | ||
| Events | |||
| Induction failure | 19 (1.9) | ||
| Relapse | 149 (15) | ||
| Death from any cause | 95 (9.5) | ||
| Treatment groups* | |||
| SR | 303 (30) | ||
| Intermediate risk | 451 (45) | ||
| High risk | 120 (12) | ||
| Extended high risk | 65 (6.5) | ||
| Discontinuation of the protocol treatment | 26 (2.6) | ||
| Age, y | <.001 | ||
| Median (range) | 5 (1-18.5) | ||
| 1-10 | 813 (81) | 1 | |
| >10 | 190 (19) | 2.6 (1.7-4.0) | |
| Sex | .3 | ||
| Female | 466 (46) | 1 | |
| Male | 537 (54) | 1.1 (0.8-1.7) | |
| Leukocyte count in peripheral blood* | <.001 | ||
| <50 × 109/L | 819 (82) | 1 | |
| ≥50 × 109/L | 183 (18) | 2.7 (1.8-4.1) | |
| NCI risk group | <.001 | ||
| SR | 671 (67) | 1 | |
| High risk | 332 (33) | 2.8 (1.9-4.2) | |
| . | n (%) . | Hazard ratio for event (95% CI) . | P . |
|---|---|---|---|
| Sample | |||
| Sample size, cases | 1003 | ||
| Follow up, median (range), y | 5.8 (0-18) | ||
| Events | |||
| Induction failure | 19 (1.9) | ||
| Relapse | 149 (15) | ||
| Death from any cause | 95 (9.5) | ||
| Treatment groups* | |||
| SR | 303 (30) | ||
| Intermediate risk | 451 (45) | ||
| High risk | 120 (12) | ||
| Extended high risk | 65 (6.5) | ||
| Discontinuation of the protocol treatment | 26 (2.6) | ||
| Age, y | <.001 | ||
| Median (range) | 5 (1-18.5) | ||
| 1-10 | 813 (81) | 1 | |
| >10 | 190 (19) | 2.6 (1.7-4.0) | |
| Sex | .3 | ||
| Female | 466 (46) | 1 | |
| Male | 537 (54) | 1.1 (0.8-1.7) | |
| Leukocyte count in peripheral blood* | <.001 | ||
| <50 × 109/L | 819 (82) | 1 | |
| ≥50 × 109/L | 183 (18) | 2.7 (1.8-4.1) | |
| NCI risk group | <.001 | ||
| SR | 671 (67) | 1 | |
| High risk | 332 (33) | 2.8 (1.9-4.2) | |
Information about final treatment risk and leukocyte count at diagnosis is missing in 38 patients and 1 patient, respectively.